Indaptus Therapeutics to Present at the LD Micro Main Event XV
October 18 2022 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that
Jeffrey A. Meckler, Chief Executive Officer will present a
corporate overview at the LD Micro Main Event XV. The conference is
being held on October 25 – 27, 2022 at the Luxe Sunset Boulevard
Hotel in Los Angeles.
Event: |
|
LD Micro Main
Event XV |
Presentation Date: |
|
Tuesday, October 25 |
Time: |
|
3:30pm PT (Track 3) |
Register to watch the presentation here.
A live webcast of the presentation can be accessed on
the investors section of the Indaptus website
https://indaptusrx.com. A replay of the webcast will be archived
and available following the event for approximately 90 days.
Mr. Meckler will be available for one-on-one
meetings throughout the conference.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of
immunotherapy advances. The Company’s approach is based on the
hypothesis that efficient activation of both innate and adaptive
immune cells and associated anti-tumor and anti-viral immune
responses will require a multi-targeted package of immune system
activating signals that can be administered safely intravenously.
Indaptus’ patented technology is composed of single strains of
attenuated and killed, non-pathogenic, Gram-negative bacteria, with
reduced i.v. toxicity, but largely uncompromised ability to prime
or activate many of the cellular components of innate and adaptive
immunity. Decoy20 represents an antigen-agnostic technology that
has produced significant single agent activity against metastatic
pancreatic and orthotopic colorectal carcinomas, single agent
eradication of established, antigen-expressing breast carcinoma, as
well as combination-mediated eradication of established
hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard
pre-clinical models, including syngeneic mouse tumors and human
tumor xenografts. Tumor eradication has been observed with Decoy
products in combination with anti-PD-1 checkpoint therapy, low-dose
chemotherapy or an approved targeted antibody. Combination-based
tumor eradication produces innate and adaptive immunological
memory, involves activation of both innate and adaptive immune
cells and is associated with induction of innate and adaptive
immune pathways in tumors after only one i.v. dose of Decoy
product, with associated “cold” to “hot” tumor inflammation
signature transition. IND-enabling toxicology studies have
demonstrated safe i.v. administration, with no sustained induction
of hallmarks of cytokine release syndromes, possibly due to passive
targeting to liver, spleen and tumor, followed by rapid elimination
of the product. Indaptus products have also produced significant
single agent activity against chronic hepatitis B virus (HBV) and
chronic human immunodeficiency virus (HIV) infections in
pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management’s expectations, beliefs and
intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations,
strategies, plans and prospects. Forward-looking statements can be
identified by the use of forward-looking words such as “believe”,
“expect”, “intend”, “plan”, “may”, “should”, “could”, “might”,
“seek”, “target”, “will”, “project”, “forecast”, “continue” or
“anticipate” or their negatives or variations of these words or
other comparable words or by the fact that these statements do not
relate strictly to historical matters. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: our plans to develop and potentially commercialize its
technology, the timing and cost of our planned investigational new
drug application and any clinical trials, the completion and
receiving favorable results in any clinical trials, Indaptus’
ability to obtain and maintain regulatory approval of any product
candidate, our ability to protect and maintain its intellectual
property and licensing arrangements, our ability to develop,
manufacture and commercialize its product candidates, the risk of
product liability claims, the availability of reimbursement, the
influence of extensive and costly government regulation, and our
estimates regarding future revenue, expenses capital requirements
and the need for additional financing. More detailed information
about the risks and uncertainties affecting us is contained under
the heading “Risk Factors” included in our most recent Annual
Report on Form 10-K filed with the SEC on March 21, 2022, and in
other filings that we have made and may make with the Securities
and Exchange Commission in the future. All forward-looking
statements speak only as of the date of this press release and are
expressly qualified in their entirety by the cautionary statements
included in this press release. We undertake no obligation to
update or revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IRScott Birkby (investors)sbirkby@coreir.com
CORE IRJules Abraham (media)917-885-7378julesa@coreir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024